Study patients were randomised to receive one of two treatments : A - RBV for 4 weeks followed by combined therapy with peg-IFN alpha-2a + RBV for 48 weeks ( n = 73 ) , or B - combined therapy with peg-IFN alpha-2a + RBV for 48 weeks ( n = 30 ) .